普瑞眼科(301239.SZ):深圳普瑞眼科目前正在按規劃籌建中,預計2024年上半年建設完工
格隆匯5月10日丨普瑞眼科(301239.SZ)於2023年5月9日下午15:00-17:00召開業績説明會,就“公司旗下的醫院診所,有多少家是處於培育虧損中,有多少家已經處於盈利中?深圳海岸城即將新開一個新的眼科醫院,目前籌備進度如何?什麼時候正式開業?這個醫院規劃為3級眼科醫院還是二級眼科醫院?”,公司表示,截止2023年一季度末,公司旗下擁有25家眼科專科醫院和3家眼科門診部。目前公司下屬醫院的盈虧平衡期大致為3-5年,3-5年院齡的醫院處於正常的培育期,在院齡4年以上的醫院中,絕大部分均已盈利,個別醫院仍在努力扭虧中。
深圳普瑞眼科目前正在按規劃籌建中,醫院按照三級醫院標準建設,預計2024年上半年建設完工,具體開業時間需要根據施工進度和取得證照的時間進行調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.